Recombinant factor VIIa (rFVIIa). Description of use in a cohort of critical patients and prognostic markers;Factor VIIa recombinante (rFVIIa). Descripción de uso en una cohorte de enfermos críticos y marcadores pronósticos

Medicina Intensiva

Volumn 31, Issue 5, 2007, Pages 215-219

  Gonzalez Castro A ^a   Suberviola Canas B ^a   Minambres E ^a   Ortiz Melon F ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Prognostic markers; Recombinant activated factor VII

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DESCRIPTIVE RESEARCH; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DRUG USE; FEMALE; HEMODYNAMICS; HOSPITALIZATION; HUMAN; INTENSIVE CARE PSYCHOSIS; LONGITUDINAL STUDY; MALE; OBSERVATIONAL STUDY; PROGNOSIS; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TIME SERIES ANALYSIS;

EID: 34547637866     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/S0210-5691(07)74813-1     Document Type: Article

References (22)

1. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Haemost. 1998;26:385-91.
2. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X in the surface of activated platelets: thoughts on the mechanism of action of high dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9:S61-5.
3. Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anaesth. 2002;49:S7-14.
4. Poon M. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol. 2001;8:312-8.
5. Shapiro AD, Gilchrist GS. Prospective, randomized trial of two doses of rFVIIa (Novoseven) in hemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773-8.
6. Kenet G. rFVIIa for profuse bleeding in surgical patients. Bloodline Rev. 2001;1:12-3.
7. Friederich P, Henny C. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet. 2003;361:201-5.
8. Hendricks H, Meijer K. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation. 2001;71:402-5.
9. Ground M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev. 2003;17:S11-21.
10. Quintana Díaz M, Cabestrero Alonso D, García de Lorenzo y Mateos A. Coagulación y hemorragia en el paciente crítico. Parte II. Factor pronóstico y tratamiento. Med Intensiva. 2003;27:676-85.
11. Ejlersen E, Melsen T, Ingerslev J. Recombinant factor VIIa acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol. 2001;36:1081-5.
12. Roberts HR. Recombinant factor VIIa (NovoSeven) and the safety of treatment. Semin Hematol. 2001;38:48-50.
13. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth. 2002;49:S15-20.
14. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth. 2003;15:184-8.
15. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion. 2003;43:1711-6.
16. Eikelboom JW, Bird R, Blythe D. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis. 2003;14:713-7.
17. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo- controlled, double- blind clinical trials. J Trauma. 2005;59:8-15.
18. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-85.
19. Mohr AM, Holcomb JB, Dutton RP, Duranteau J. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma. Crit Care. 2005;9 Suppl 5:S37-42.
20. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. 2005;93:1027-35.
21. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883-90.
22. Lam MS, Sims-McCallum RP. Recombinant factor VIIa in the treatment of non-hemophiliac bleeding. Ann Pharmacother. 2005;39:885-91.